Risk of relapse of multiple myeloma following kidney transplantation
Sapna Shah(King's College London), Reuben Benjamin(King's College London), Maria Ibrahim(King's College Hospital), Matthew Streetly(King's College - North Carolina), Michael P. Delaney(East Kent Hospitals University NHS Foundation Trust), Ceri Bygrave(Cardiff and Vale University Health Board), Steve Schey(King's College London)
Cited by 27
Related Papers
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
|Blood|2023|330
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315